Literature DB >> 23839869

Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection.

David M Gracey1, Paul Snelling, Paul McKenzie, Simone I Strasser.   

Abstract

Tenofovir disoproxil fumarate (TDF) is increasingly used in patients with chronic hepatitis B (CHB) infection. Although associated with renal toxicity in HIV-infected patients, renal dysfunction has been reported rarely in the monoinfected CHB population. To date, TDF-associated Fanconi syndrome has not been reported. Here, we present two cases of TDF-associated Fanconi syndrome with rapid resolution after its cessation. We then discuss risk factors for TDF nephrotoxicity and its implications for screening for renal disease in those patients with CHB monoinfection on TDF, and the use of TDF in at-risk populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23839869     DOI: 10.3851/IMP2649

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  27 in total

1.  Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.

Authors:  Yun Bin Lee; Jeong-Hoon Lee; Dong Hyeon Lee; Hyeki Cho; Hongkeun Ahn; Won-Mook Choi; Young Youn Cho; Minjong Lee; Jeong-Ju Yoo; Yuri Cho; Eun Ju Cho; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Chung Yong Kim; Hyo-Suk Lee
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.

Authors:  Maile Young Karris
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-12       Impact factor: 2.205

Review 3.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 4.  Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.

Authors:  Lili Chan; Benjamin Asriel; Ellen F Eaton; Christina M Wyatt
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-03       Impact factor: 2.894

5.  Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response.

Authors:  Hyun Woong Lee; Jae-Cheol Kwon; In Soo Oh; Hye Young Chang; Young Joo Cha; Ik-Seong Choi; Hyung Joon Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

6.  Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.

Authors:  Connie Tien; Jason J Xu; Linda S Chan; Mimi Chang; Carolina Lim; Sue Lee; Brian Huh; Shuntaro Shinada; Ho S Bae; Tse-Ling Fong
Journal:  Dig Dis Sci       Date:  2014-09-20       Impact factor: 3.199

7.  Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome.

Authors:  T-L Chung; N-C Chen; C-L Chen
Journal:  Osteoporos Int       Date:  2018-08-31       Impact factor: 4.507

Review 8.  Current and future directions for treating hepatitis B virus infection.

Authors:  Akinobu Tawada; Tatsuo Kanda; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-06-18

9.  Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.

Authors:  Fabien Zoulim; Jolanta Białkowska-Warzecha; Mircea Mihai Diculescu; Adrian Eugen Goldis; Renate Heyne; Tomasz Mach; Patrick Marcellin; Jörg Petersen; Krzysztof Simon; Soumaya Bendahmane; Isabelle Klauck; Wojciech Wasiak; Harry L A Janssen
Journal:  Hepatol Int       Date:  2016-05-20       Impact factor: 6.047

10.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.